	US 11,672,827 B2
	Pharmaceutical chimeric receptor composition and method thereof
Te-Ling Pang, Taipei (TW); Ming Chin Ko, Taitung (TW); Yi Han Dai, Tainan (TW); and Yi-Ting Lai, Taichung (TW)
Appl. No. 16/955,766
Filed by UWELL BIOPHARMA INC., New Taipei (TW)
PCT Filed Aug. 9, 2018, PCT No. PCT/CN2018/099502 § 371(c)(1), (2) Date Jun. 18, 2020, PCT Pub. No. WO2019/119822, PCT Pub. Date Jun. 27, 2019.
Claims priority of provisional application 62/610,156, filed on Dec. 23, 2017.
Prior Publication US 2021/0069244 A1, Mar. 11, 2021
Int. Cl. A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); C07K 16/46 (2006.01); C12N 5/10 (2006.01); C12N 15/85 (2006.01)

CPC A61K 35/17 (2013.01) [C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70525 (2013.01); C07K 14/70578 (2013.01); C07K 16/46 (2013.01); C12N 5/10 (2013.01); C12N 15/85 (2013.01)]

10 Claims

1. An expression vector of an artificial chimeric antigen receptor (CAR), comprising:

a CD 19 antigen-binding fragment sequence comprising a nucleic acid sequence encoding a heavy chain variable domain, a light chain variable domain and a linker,

wherein the nucleic acid sequence of the heavy chain variable domain is SEQ ID NO: 2 and the nucleic acid sequence of the light chain variable domain is SEQ ID NO: 1,

or the nucleic acid sequence of the heavy chain variable domain is SEQ ID NO: 4 and the nucleic acid sequence of the light chain variable domain is SEQ ID NO: 3,

or the nucleic acid sequence of the heavy chain variable domain is SEQ ID NO: 6 and the nucleic acid sequence of the light chain variable domain is SEQ ID NO: 5;

a transmembrane domain sequence comprising a nucleic acid sequence encoding a transmembrane sequence of CD28, IgG1, CD4, CD8a or any combination thereof; and a signaling domain sequence comprising a nucleic acid sequence encoding at least one immunoreceptor tyrosine-based activation motif (ITAM) sequence, at least one co-stimulatory molecule (CM) sequence, or combination thereof.